KPIs & Operating Metrics(New)
Breakdown Of AssetsCollaborative Agreement Revenue BreakdownCollaborative Agreement Revenue Breakdown AnnualCommercial Revenue By CategoryCommercial Revenue By Category AnnualContractual Obligations AnnualContractual Obligations TotalCost Of SalesDeferred RevenueEmployee StatisticsGross Margin %Gross ProfitIncome (Loss) Before Income TaxNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX SegregationProperty, Plant And Equipment, Net BreakdownRaw Materials By SegmentR&D Revenue By CategoryR&D Revenue By Category AnnualR&D Revenue By Category (Deprecated)Revenue By SegmentRevenue By Segment %Revenue By Segment AnnualRevenue By Segment Annual %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Gross Profit (2021 - 2025)

Ionis Pharmaceuticals has reported Gross Profit over the past 8 years, most recently at $195.4 million for Q4 2025.

  • Quarterly results put Gross Profit at $195.4 million for Q4 2025, down 12.29% from a year ago — trailing twelve months through Dec 2025 was $477.8 million (down 31.15% YoY), and the annual figure for FY2025 was $927.8 million, up 33.7%.
  • Gross Profit for Q4 2025 was $195.4 million at Ionis Pharmaceuticals, up from $154.4 million in the prior quarter.
  • Over the last five years, Gross Profit for IONS hit a ceiling of $321.4 million in Q4 2023 and a floor of -$2.2 million in Q2 2025.
  • Median Gross Profit over the past 5 years was $135.2 million (2022), compared with a mean of $147.2 million.
  • Biggest five-year swings in Gross Profit: skyrocketed 1129.4% in 2021 and later plummeted 100.97% in 2025.
  • Ionis Pharmaceuticals' Gross Profit stood at $57.8 million in 2021, then soared by 156.52% to $148.2 million in 2022, then skyrocketed by 116.89% to $321.4 million in 2023, then crashed by 30.7% to $222.7 million in 2024, then fell by 12.29% to $195.4 million in 2025.
  • The last three reported values for Gross Profit were $195.4 million (Q4 2025), $154.4 million (Q3 2025), and -$2.2 million (Q2 2025) per Business Quant data.